POTENSI INTERAKSI OBAT PADA RESEP POLIFARMASI (STUDI KASUS: APOTEK MUTIARA HATI DAN APOTEK PURI DAGO BANDUNG)

• Main Author: Kuning, Cempaka
• Format: Final Project
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/39035
• Institution: Institut Teknologi Bandung

Polypharmacy prescription very commonly occurs on prescribing the outpatient and inpatient in health facilities such as hospitals and pharmacies. Polypharmacy may increase the risk of Drug-drug Interactions (DDI’s) which mostly causes harm impact in the patient’s therapy. Drug interactions considered clinically significant if it increases the toxicity and/or decreases the effectiveness of therapy. The objective of this study was to determine the number of potential drug interactions in polypharmacy prescriptions. This study was a non-experimental study that was carried out retrospectively by taken prescription data received by Mutiara Hati Pharmacy and Puri Dago Pharmacy in Bandung for the period of October – December 2018. Samples were obtained by purposive sampling technique and were analyzed by using Stockley’s Drug Interaction 9th Edition and Drug Interactions Facts (Tatro, 2009), as well as micromedexsolutions.com database to determine the potential for drug interactions based on its severity and interaction mechanism. Of the 1218 prescription sheets analyzed, 896 prescription sheets (73.56%) were included in the inclusion criteria, with 569 prescription sheets (63.50%) with 1035 events of potential drug interactions. Based on the severity, minor interactions were found as 96 events (9.28%), moderate interactions were found as 886 events (85.60%), and major interactions were found as 53 events (5.12%). Based on the interaction mechanism, pharmacokinetic interactions were found as 100 events (9.66%), and pharmacodynamic interactions were found as 935 events (90.34%). Based on the many potential drug interactions, polypharmacy prescribing should be avoided and management of potential DDI’s should be performed.